Bayer seeks regorafenib new drug application approval
The oral multi-kinase inhibitor regorafenib is used for the treatment of metastatic and unresectable gastrointestinal stromal tumors (GIST) in pre treated patients with advance in disease. The application
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.